Scientific Poster

In the field of therapeutic antibody production, diversification of fed-batch strategies is flourishing inresponse to the market demand. All manufacturing approaches tend to follow the generally accepted dogmaof increasing titer since it directly increases manufacturing output. While titer is...

Assessing and controlling aggregation of biologics is vital to ensure the safety and efficacy of a biopharmaceutical product. In addition, aggregation has been recognized as a major issue for modern therapeutic modalities such as bispecific antibodies and Fc fusion proteins. Therefore, checking for...

As biotherapeutics development using mammalian cell platforms continues to grow, continuous improvement and optimization of cell line development processes are crucial. Selexis’ cell line development platform requires routine passaging of hundreds of suspension-adapted cell lines. Traditionally,...

Chinese hamster ovary (CHO) cells represent the most frequently applied host cell system for industrial manufacturing of recombinant protein therapeutics. Generating and identifying high producing clones in a fast and efficient way such that they do not lose their expression capability over time...

Recombinant therapeutic protein production processes must guarantee a sufficiently small variability in the product quality. To keep this variability low, it is critical to run the process in a totally reproducible way. This requires controlling all cultivation parameters. The use of new analyzers,...

In an effort to improve product yield of mammalian cell lines, we have previously demonstrated that our proprietary DNA elements, Selexis Genetic Elements (SGEs), increase the transcription of a given transgene1, thus boosting the overall expression of a therapeutic protein drug in mammalian cells....

The development of new mammalian expression platforms represents an ongoing need for advancing biophar-maceuticals towards human clinical trials.